For instance, dexamethasone is known to have a strong inhibitory effect on IL6 and IL17A in patients with COVID-19 (42), but it is still unclear to what extent the beneficial effects of IL-6 blockers depend on dose, time of administration, clinical condition, among other factors (43, 44). This evidence concerns the gene IL17A and COVID-19.